BUDGET IMPACT ANALYSIS OF TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN ADULT PATIENTS WITH BARICITINIB IN THE RUSSIAN FEDERATION

被引：0
|
作者：
Yagudina, R. [1 ]
Kulikov, A. [1 ]
Serpik, V [1 ]
Protsenko, M. [1 ]
机构：
[1] Sechenov Univ, Sechenov First Moscow State Med Univ, Moscow, Russia
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY13
引用
收藏
页码：S903 / S903
页数：1
相关论文
共 50 条
  • [41] EFFICACY OF BARICITINIB IN PATIENTS WITH MODERATE TO-SEVERE RHEUMATOID ARTHRITIS WITH 3 YEARS OF TREATMENT: RESULTS FROM A LONG-TERM STUDY
    Smolen, Josef S.
    Xie, Li
    Jia, Bochao
    Taylor, Peter C.
    Burmester, Gerd
    Tanaka, Yoshiya
    Elias, Ayesha
    Cardoso, Anabela
    Ortmann, Rob
    Walls, Chad
    Dougados, Maxime
    Alberto Barragan, Jorge
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S110 - S110
  • [42] Tuberculosis, Potential Opportunistic Infections, and Other Infections of Interest in Patients with Moderate to Severe Rheumatoid Arthritis in the Baricitinib Program
    Winthrop, Kevin
    Lindsey, Stephen
    Harigai, Masayoshi
    Bradley, John D.
    Chen, Lei
    Hyslop, David L.
    Issa, Maher
    Nishikawa, Atsushi
    Witt, Sarah
    Dickson, Christina L.
    Dougados, Maxime
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [43] EFFICACY OF BARICITINIB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS WITH 3 YEARS OF TREATMENT: RESULTS FROM A LONG-TERM STUDY
    Smolen, J. S.
    Xie, L.
    Jia, B.
    Taylor, P. C.
    Burmester, G. R.
    Tanaka, Y.
    Elias, A.
    Cardoso, A.
    Ortmann, R.
    Walls, C.
    Dougados, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1012 - 1012
  • [44] Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study
    Caporali, Roberto
    Taylor, Peter C.
    Aletaha, Daniel
    Sanmarti, Raimon
    Takeuchi, Tsutomu
    Mo, Daojun
    Haladyj, Ewa
    Bello, Natalia
    Zaremba-Pechmann, Liliana
    Fang, Ying
    Dougados, Maxime
    RHEUMATOLOGY, 2024, 63 (10) : 2799 - 2809
  • [45] Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
    Li, SiNi
    Li, JianHe
    Peng, LiuBao
    Li, YaMin
    Wan, XiaoMin
    RHEUMATOLOGY AND THERAPY, 2021, 8 (02) : 863 - 876
  • [46] EFFICACY OF BARICITINIB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS WITH 3 YEARS OF TREATMENT: RESULTS FROM A LONG-TERM STUDY
    Bird, Paul
    Smolen, Josef S.
    Xie, Li
    Jia, Bochao
    Taylor, Peter C.
    Burmester, Gerd
    Tanaka, Yoshiya
    Elias, Ayesha
    Cardoso, Anabela
    Ortmann, Rob
    Walls, Chad
    Dougados, Maxime
    INTERNAL MEDICINE JOURNAL, 2021, 51 : 23 - 23
  • [47] Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
    SiNi Li
    JianHe Li
    LiuBao Peng
    YaMin Li
    XiaoMin Wan
    Rheumatology and Therapy, 2021, 8 : 863 - 876
  • [48] MICROARRAY PATHWAY ANALYSIS COMPARING BARICITINIB AND ADALIMUMAB IN MODERATE TO SEVERE RHEUMATOID ARTHRITIS FROM A PHASE 3 STUDY
    Emery, P.
    Taylor, P. C.
    Weinblatt, M. E.
    Tanaka, Y.
    Keystone, E. C.
    Dow, E. R.
    Higgs, R.
    Macias, W. L.
    Rocha, G.
    Rooney, T. P.
    Schlichting, D. E.
    Zuckerman, S. H.
    McInnes, I. B.
    Holzkaemper, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : A52 - A52
  • [49] LEFLUNOMIDE IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN POLAND-A BUDGET IMPACT ANALYSIS
    Golicki, D.
    Niewada, M.
    Lis, J.
    Tlustochowicz, W.
    VALUE IN HEALTH, 2008, 11 (06) : A540 - A540
  • [50] Budget impact analysis of the use of rituximab in the treatment of rheumatoid arthritis in Italy
    Benucci, Maurizio
    Iannazzo, Sergio
    Sabadini, Luciano
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2009, 10 (01) : 19 - 31
12345